Success Metrics

Clinical Success Rate

100.0%

Based on 2 completed trials

Completion Rate

100%(2/2)

Active Trials

1(25%)

Results Posted

50%(1 trials)

Phase Distribution

Ph phase_3

25%

Ph phase_2

75%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution4 total trials

Phase 2Efficacy & side effects

3(75.0%)

Phase 3Large-scale testing

1(25.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

2 of 2 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Active(2)

Completed(2)

Detailed Status

Completed2

Active, not recruiting1

Not yet recruiting1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

100.0%

Most Advanced

Phase 3

Trials by Phase

Phase 23 (75.0%)

Phase 31 (25.0%)

Trials by Status

active_not_recruiting125%

completed250%

not_yet_recruiting125%

Recent Activity

1 active trials

Showing 4 of 4

active_not_recruitingphase_3

Determine Effectiveness of Anifrolumab In SYstemic Sclerosis (DAISY)

NCT05925803

not_yet_recruitingphase_2

Investigation of Vancomycin Efficacy in Patients With Ulcerative Colitis and Primary Sclerosing Cholangitis

NCT07341282

completedphase_2

Dupilumab in Eosinophilic Gastritis

NCT03678545

completedphase_2

A Dose-ranging Study in Patients With Diabetic Peripheral Neuropathic Pain (DPNP)

NCT06203002

Clinical Trials (4)

Showing 4 of 4 trials

NCT05925803Phase 3

Determine Effectiveness of Anifrolumab In SYstemic Sclerosis (DAISY)

Active Not Recruiting

NCT07341282Phase 2

Investigation of Vancomycin Efficacy in Patients With Ulcerative Colitis and Primary Sclerosing Cholangitis

Not Yet Recruiting

NCT03678545Phase 2

Dupilumab in Eosinophilic Gastritis

Completed

NCT06203002Phase 2

A Dose-ranging Study in Patients With Diabetic Peripheral Neuropathic Pain (DPNP)

Completed

All 4 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 4